Abstract:Recent successes in cancer immunotherapy have been tempered by sub-optimal clinical responses in the majority of patients. The impaired anti-tumor immune responses observed in these patients are likely a consequence of immune system dysfunction contributed to by a variety of factors that include, but are not limited to, diminished antigen presentation/detection, leukopenia, a coordinated network of immunosuppressive cell surface proteins, cytokines and cellular mediators. Monocytes that have diminished or no HLA-DR expression, called CD14+HLA-DRlo/neg monocytes, have emerged as important mediators of tumor-induced immunosuppression. These cells have been grouped into a larger class of suppressive cells called myeloid derived suppressor cells (MDSCs) and are commonly referred to as monocytic myeloid derived suppressor cells. CD14+HLA-DRlo/neg monocytes were first characterized in patients with sepsis and were shown to regulate the transition from the inflammatory state to immune suppression, ultimately leading to immune paralysis. These immunosuppressive monocytes have also recently been shown to negatively affect responses to PD-1 and CTLA-4 checkpoint inhibition, CAR-T cell therapy, cancer vaccines, and hematopoietic stem cell transplantation. Ultimately, the goal is to understand the role of these cells in the context of immunosuppression not only to facilitate the development of targeted therapies to circumvent their effects, but also to potentially use them as a biomarker for understanding disparate responses to immunotherapeutic regimens. Practical aspects to be explored for development of CD14+HLA-DRlo/neg monocyte detection in patients are the standardization of flow cytometric gating methods to assess HLA-DR expression, an appropriate quantitation method, test sample type, and processing guidances. Once detection methods are established that yield consistently reproducible results, then further progress can be made toward understanding the role of CD14+HLA-DRlo/neg monocytes in the immunosuppressive state.

CD14: Biology and role in the pathogenesis of disease

Soluble CD40 Ligand Stimulates CD40-Dependent Activation of the Β2 Integrin Mac-1 and Protein Kinase C Zeda (pkcζ) in Neutrophils: Implications for Neutrophil-Platelet Interactions and Neutrophil Oxidative Burst

[CD14 protein as a modulator of the inflammatory response]

A comprehensive review of the literature on CD10: its function, clinical application, and prospects

TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling

CD44 Clustering is Involved in Monocyte Differentiation

CD14 is a key mediator of both lysophosphatidic acid and lipopolysaccharide induction of foam cell formation

Elevated CD169 expressing monocyte/macrophage promotes systemic inflammation and disease progression in cirrhosis

The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage.

The biological function and significance of CD74 in immune diseases

CD300e: Emerging role and mechanism as an immune-activating receptor

A LY6E-PHB1-TRIM21 Assembly Degrades CD14 Protein to Mitigate LPS-induced Inflammatory Response.

The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy

The role of CD74 in cardiovascular disease

From Molecular Mechanisms to Clinical Applications

CD14 blockade to prevent ischemic injury to donor organs

Toll-like receptor 4: A potential therapeutic target for multiple human diseases

Toll-like receptors in inflammation, infection and cancer

CD14 is a decision-maker between Fas-mediated death and inflammation

Activated Platelets Convert CD14+CD16- Into CD14+CD16+ Monocytes With Enhanced FcγR-Mediated Phagocytosis and Skewed M2 Polarization

CD16+ monocytes give rise to CD103+RALDH2+TCF4+ dendritic cells with unique transcriptional and immunological features